LA · State regulatory reference

Louisiana.

Restrictive

Louisiana pairs a permissive telemedicine baseline (La. R.S. 37:1271 and the Telehealth Access Act, R.S. 40:1223.1 et seq., allow audio-video initial visits and prescribing) with a distinctive, in-force restriction directly relevant to peptides: the Board of Medical Examiners' rule LAC 46:XLV.7513 prohibits using telemedicine 'for the treatment of obesity' and bars telemedicine controlled-substance prescribing without an in-person visit in the prior year. The Board of Pharmacy has also disciplined GLP-1 compounding — 2023 consent orders against pharmacies using unapproved semaglutide-sodium salt forms (Cases 23-0086/23-0087) — though those two flagship orders were rescinded in May 2024 after corrected certificates of analysis. Compounding otherwise follows USP <795>/<797>/<800> and FDCA 503A under LAC 46:LIII Ch. 25.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Louisiana Medical Board

https://www.lsbme.la.gov/ ↗

Pharmacy board

Louisiana Board of Pharmacy

https://www.pharmacy.la.gov/ ↗

TPC notes

Telehealth

R.S. 37:1271 and the Telehealth Access Act generally allow establishing a new patient relationship and prescribing via synchronous audio-video, but LAC 46:XLV.7513 flatly prohibits telemedicine 'for the treatment of obesity' and requires an in-person visit within the prior year before any telemedicine controlled-substance prescription. GLP-1s are not controlled substances, so the obesity-treatment clause is the operative limit on weight-loss telehealth.

Compounding

The Board of Pharmacy adopts USP <795>/<797>/<800> and FDCA 503A via LAC 46:LIII Ch. 25 Subch. C and has policed GLP-1 compounding — disciplining pharmacies for unapproved semaglutide-sodium salt forms in 2023, though the two lead board orders were rescinded in May 2024 after corrected COAs.

Sources